Amgen Inc. (NASDAQ:AMGN) Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,853 shares of the medical research company's stock after acquiring an additional 5,373 shares during the quarter. Amgen accounts for about 0.5% of Illinois Municipal Retirement Fund's portfolio, making the stock its 23rd biggest holding. Illinois Municipal Retirement Fund's holdings in Amgen were worth $30,488,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Briaud Financial Planning Inc acquired a new stake in Amgen during the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the 4th quarter worth about $29,000. OFI Invest Asset Management acquired a new stake in Amgen during the 3rd quarter worth about $26,000. Planned Solutions Inc. acquired a new stake in Amgen during the 4th quarter worth about $30,000. Finally, Providence Capital Advisors LLC acquired a new stake in Amgen during the 3rd quarter worth about $30,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Amgen stock traded up $2.98 during trading hours on Monday, reaching $271.91. 2,165,532 shares of the company were exchanged, compared to its average volume of 2,849,916. The firm has a market cap of $145.85 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.50 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock has a 50-day moving average of $276.45 and a 200 day moving average of $281.56. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion during the quarter, compared to analysts' expectations of $8.13 billion. During the same quarter in the prior year, the business earned $4.09 earnings per share. The company's revenue was up 19.8% on a year-over-year basis. As a group, research analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.31%. Amgen's dividend payout ratio is 72.06%.

Analysts Set New Price Targets

Several research firms have issued reports on AMGN. Raymond James started coverage on Amgen in a report on Thursday, March 28th. They set a "market perform" rating on the stock. Oppenheimer reiterated an "outperform" rating and issued a $350.00 target price on shares of Amgen in a report on Thursday, February 1st. The Goldman Sachs Group upped their target price on Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a report on Wednesday, February 7th. StockNews.com downgraded Amgen from a "buy" rating to a "hold" rating in a report on Thursday, March 28th. Finally, Truist Financial reiterated a "buy" rating and issued a $320.00 target price on shares of Amgen in a report on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.